Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Polish Journal of Surgery

The Journal of Foundation of the Polish Journal of Surgery

12 Issues per year


CiteScore 2016: 0.29

SCImago Journal Rank (SJR) 2015: 0.214
Source Normalized Impact per Paper (SNIP) 2015: 0.336

Open Access
Online
ISSN
0032-373X
See all formats and pricing
In This Section
Volume 80, Issue 8 (Aug 2008)

Issues

ε-Aminocaproic Acid (EACA)

Marek Gacko
  • Department of Vascular Surgery and Transplantation, Medical University, Białystok
/ Anna Worowska
  • Department of Vascular Surgery and Transplantation, Medical University, Białystok
Published Online: 2008-09-10 | DOI: https://doi.org/10.2478/v10035-008-0059-5

ε-Aminocaproic Acid (EACA)

  • Gabriel S, Maass TA: Ueber ε-aminocapronsäure. Ber Dtsch Chem Ges 1899; 32: 1266-72.CrossrefGoogle Scholar

  • Okamoto S, Nakajima T, Okamoto U et al.: A suppresing effect of ε-amino-n-caproic acid and the bleeding of dogs, produced with the activation of plasmin in the circulatory blood. Keio J Med 1959; 8: 247-56.CrossrefGoogle Scholar

  • Niewiarowski S: Untersuchungen über die hämostatische wirkung von ε-aminokapronsäure (EACA). Z Ges Inn Med 1965; 7: 323-25.Google Scholar

  • Westlund LE, Lunden R, Wallen P: Effect of EACA, PAMBA, AMCHA and AMBOCA on fibrynolysis induced by streptokinase, urokinase and tissue activator. Haemostasis 1982; 11: 235-41.Google Scholar

  • Łukasiewicz H, Niewiarowski S, Worowski K et al.: The plazmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate. Biochim Biophys Acta 1968; 159: 503-08.CrossrefGoogle Scholar

  • Mathews II, Vanderhoff P, Castellino FJ et al.: Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands ε-aminocaproic acid and trans-4-/aminomethyl/cyclohexane-1-carboxylic acid. Biochemistry, 1996; 35: 2567-76.Google Scholar

  • McClung WG: Interactions of fibrinolytic system proteins with lysine-containing surfaces. J Biomed Mater Res Part A. 2003; 66A: 795-801.CrossrefGoogle Scholar

  • Okamoto S, Oshiba S, Mihara H et al.: Synthetic inhibitors of fibrynolysis: in vitro and in vivo action. Ann NY Acad Sci 1968; 146: 414-29.CrossrefGoogle Scholar

  • Winn ES, Hu SP, Hochschwender SM et al.: Studies on the lysine-binding sites of human plasminogen. The effect of ligand structure on the binding of lysine analogs to plasminogen. Eur J Biochem 1980; 104: 579-86.CrossrefPubMedGoogle Scholar

  • Midura-Nowaczek K: Low molecular inhibitors of plasmin. Wiad Chem 1998; 52: 11-12.Google Scholar

  • Griffin JD, Ellman L: Epsilon-aminocaproic acid (EACA). Sem Thrombos Haemotas 1978; 5: 27-40.Google Scholar

  • Schwartz BS, Williams EC, Conlan et al.: Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Int Med 1986; 105: 873-77.CrossrefGoogle Scholar

  • Levy JH: Hemostatic agents and their safety. J Cardiothorac Vasc Anesth 1999; 13: 6-11.Google Scholar

  • Nielsen VG, Cankovic L, Steenwyk BK: ε-aminocaproic acid inhibition of fibrynolisis in vitro: should therapeutic concentration be reconside? Blood Coagulat Fibrynol 2007; 18: 35-39.CrossrefGoogle Scholar

  • McNicol GP, Fletcher APAlkjaersig N et al.: Absorption, distribution, and excretion of ε-aminocapronic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59: 15-24.Google Scholar

  • Kostro B, Prokopowicz J, Serwatko A: Investigation on acute and chronic toxicity of epsilon-aminocapronic acid. Acta Physiol Pol 1964; 15: 372-79.Google Scholar

  • Frederiksen MC, Bowsher DJ, Ruo et al.: Kinetics of epsilon-aminocaproic acid distribution, elimination and antifibrinolytic effects in normal subjects. Clin Pharmacol Ther 1984; 35: 387-93.CrossrefGoogle Scholar

  • Vander Salm TJ, Kaur S, Lancey RA et al.: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovas Surg 1996; 112: 1098-1107.Google Scholar

  • Bonnett-Guerrero E, Sorohan JG, Canada AT et al.: Mythen MG. ε-aminocaproic acid plasma levels during cardiopulmonary by-pass. Anesth Analg 1997; 85: 248-51.Google Scholar

  • Slaughter TF, Faghih F, Greenberg CS et al.: The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997; 85: 1221-26.PubMedGoogle Scholar

  • Kluger R, Olive DJ, Stewart AB et al.: Epsilonaminocaproic acid in coronary artery bypass graft surgery. Anesthesiology 2003; 99: 1263-69.CrossrefGoogle Scholar

  • Kikura M, Levy JH, Tanaka KA et al.: A doublebind placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202: 216-22.Google Scholar

  • Munoz JJ, Birkmeyer NJ, Birkmeyer JD et al.: Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999; 99: 81-89.PubMedCrossrefGoogle Scholar

  • Szczurek D, Andres J, Drwiła R et al.: The effects of tramaxamic acid and aprotinin on postoperative loss in coronary artery bypass surgery. Anestez Intens Terap 2001; 33: 247-49.Google Scholar

  • Choi TS, Greilich PE, Shi C et al.: Point-of-care testing for prethrombin time, but not activated partial thromboplastin time, correlates with laboratory methods in patients receving aprotinin or epsilon-aminocapronic acid while undergoing cardiac surgery. Am J Clin Pathol 2002; 117: 74-78.Google Scholar

  • Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.CrossrefGoogle Scholar

  • Suwalski G: Aprotinina - postępowanie antyfibrynolityczne w kardiochirurgii. Kardiol po Dypl 2006; 5: 10-21.Google Scholar

  • Bridges CR: Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation 2007; 115: 2790-92.CrossrefPubMedGoogle Scholar

  • Brown J, Birkmeyer NJO, O'Conner GT: Meta-analysis comparing the effectiveness and adverse outcoms of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-13.CrossrefGoogle Scholar

  • Pitts TO, Spero JA, Bontempo FA et al.: Acute renal failure due to high-grade obstruction following therapy with ε-aminocaproic acid. Am J Kidney Dis 1986; 8: 441-44.PubMedGoogle Scholar

  • Manjunath G, Fozailoff A, Mitcheson D et al.: Epsilon-aminocaproic acid and renal complications: case report and review of the literature. Clin Nephrol 2002; 58: 63-67.PubMedCrossrefGoogle Scholar

  • Worowski K: Synergestic antifibrinolytic action of the potato protease inhibitor and ε-aminocaproic acid. Acta Biol Acad Sci Hung 1976; 27: 125-28.Google Scholar

  • Smokovitz A, Kuintzis S, Kutsouris C et al.: The effects of intrafollicular iniection of plasmin and ε-aminocaproic acid on the ovulation in the ewe. Fibrinolysis 1989; 3: 227-30.Google Scholar

  • Nilsson IM, Sjoerdsma A, Waldenstrom J: Antifibrinolytic activity and metabolism of ε-aminocaproic acid in man. Lancet 1960; 18: 1322-26.CrossrefGoogle Scholar

  • Vogt W, Schmiat G, Lynen R et al.: Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid. J Immunol 1975; 114: 671-77.Google Scholar

  • Wołosowicz N, Niewiarowski S: The in-vivo-effect of ε-aminocaproic acid (EACA) on human plasma fibrinolytic system. Thrombos Diathes Haemorrhag 1966; 15: 491-500.Google Scholar

  • Glick R, Green D, Tsao C et al.: Hig dose ε-aminocaproic acid prolongs the bleeding time and increase rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery 1981; 9: 398-401.Google Scholar

  • Green D, Tsao CH, Cerullo L et al.: Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. J Lab Clin Med 1985; 105: 321-27.Google Scholar

  • Sjoerdsma A, Hanson A: Determination of ε-aminocaproic acid in urine by means of high valtage electrophoresis. Acta Chem Scand 1959; 13: 2150-54.CrossrefGoogle Scholar

  • Mc Nicol GP, Fletcher AP, Alkjaersig N et al.: Plasma amino acid chromatography with ion exchange resin loaded paper: assay of ε-aminocaproic acid. J Lab Clin Med 1962; 59: 7-12.Google Scholar

  • Farid NA: Fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum. J Pharm Sci 1979; 68: 249-52.CrossrefPubMedGoogle Scholar

  • Lam S: High performance liquid chromatographic assay of Amicar ε-aminocaproic acid in plasma and urine after pre-column derivatization with o-phthalaldehyde for fluorescence detection. Biomed Chromatogr 1990; 4: 175-77.CrossrefGoogle Scholar

  • Wołosowicz N, Niewiarowski S, Czerepko K: Method for determining ε-aminocaproic acid (EACA) in blood plasma, based on the antifibrinolytic properties of the compound. Thromb Diath Haemorrh 1964; 10: 309-16.Google Scholar

  • Wołosowicz N, Niewiarowski S: A simpll method of determining ε-aminocaproic acid (EACA) in urine. Clin Chim Acta 1965; 12: 555-57.PubMedCrossrefGoogle Scholar

  • Blix S: The euglobulin method for estimation of fibrinolytic activity in streptokinase-activated plasma. Scand J Clin Lab Invest 1962; 14: 528-32.PubMedCrossrefGoogle Scholar

  • Deutsch DG, Mertz ET: Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-96.PubMedCrossrefGoogle Scholar

  • Rosenberg AA, Peabody RA: Rapid estimation of fibrinogen in fibrinolytic and nonfibrinolytic states. Clin Chem 1972; 18: 666-68.Google Scholar

  • Steffen LW, Steffen BW: Improved method for measuring fibrinogen in plasma, with use of a plasmin inhibitor. Clin Chem 1976; 22: 381-83.PubMedGoogle Scholar

  • Stassano P, Musumeci A, Santise G et al.: Can ε-aminocaproic acid balance the off-pump bleeding advantage? Cardiovasc Surg 2003; 11: 219-24.CrossrefGoogle Scholar

  • Greilich PE, Brouse CF, Rinder CS et al.: Effects of ε-aminocaproic acid and aprotinin on leuko-cyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 2004; 100: 225-33.CrossrefGoogle Scholar

  • Johnson AJ, Skoza L: Chemical determination of epsilon aminocaproic acid, an inhibitor of plasminogen activation. Fed Proc 1961; 20: 59-62.Google Scholar

  • Czerepko K, Wołosowicz N: Analysis of aqueous mixtures of ε-aminocaproic acid and α,ε-diaminocaproic acid using ninhydryn. Talanta 1963; 10: 813-16.CrossrefGoogle Scholar

  • Lammle B, Duckert F: Different assessment of plasmin with different substrates. In vitro alteration of plasmin, influence of ε-aminocaproic acid and tranexamic acid upon its activity. Thromb Haemost 1980; 43: 112-17.PubMedGoogle Scholar

  • Wu TP, Padmanabhan K, Tulinsky A et al.: The refined structure of the ε-aminocaproic acid complex of human plasminogen kringle 4. Biochemistry 1991; 30: 10589-94.Google Scholar

  • Anonick PK, Vasudevan J, Gonias SL: Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition. Arterioscler Thrombos 1992; 12: 708-16.CrossrefGoogle Scholar

About the article


Published Online: 2008-09-10

Published in Print: 2008-08-01


Citation Information: Polish Journal of Surgery, ISSN (Print) 0032-373X, DOI: https://doi.org/10.2478/v10035-008-0059-5.

Export Citation

This content is open access.

Comments (0)

Please log in or register to comment.
Log in